Your session is about to expire
← Back to Search
Pembrolizumab for Lung Cancer
Study Summary
This trial is testing how well pembrolizumab works against non-squamous non-small cell lung cancer that has spread to other parts of the body. Monoclonal antibodies might prevent tumor cells from growing and spreading.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this the only clinical trial that has been done using Pembrolizumab?
"Pembrolizumab is being researched in over 1000 ongoing studies, 122 of which are in the third and final phase. The majority of these investigations are taking place in Houston, Texas; however, there are 36053 locations worldwide running clinical trials for this immunotherapy treatment."
Across how many people is this experiment being conducted?
"Unfortunately, this particular clinical trial is no longer enlisting patients. This study was first posted on October 1st, 2016 and experienced its most recent update on December 21st, 2021. There are currently 1393 other trials for carcinoma, non-small-cell lung cancer and 1000 Pembrolizumab studies that are actively searching for participants."
Is it generally well-tolerated for patients to take Pembrolizumab?
"While there are no Phase 2 trials supporting pembrolizumab's efficacy, there is some data backing its safety which gives it a score of 2."
Are new participants being accepted for this experiment at this time?
"This particular study is not recruiting patients at the moment, as per the most recent information available on clinicaltrials.gov. This trial was first posted on October 1st, 2016 and last updated December 21st, 2021. There are 2393 other trials which are currently open for recruitment."
Share this study with friends
Copy Link
Messenger